Ascentage Pharma Group International - Unsponsored ADR
AAPG Healthcare Biotechnology
Ascentage Pharma Group International - Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $82.1 million, down 38.9% from fiscal 2024.
Follow AAPG
Ascentage Pharma Group International - Unsponsored ADR (AAPG) Piotroski F-score
Ascentage Pharma Group International - Unsponsored ADR's Piotroski F-score for fiscal 2025 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 3 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (38.41%) | (15.81%) | Fail | 0 |
| Positive operating cash flow | (167.90m) | (15.26m) | Fail | 0 |
| Rising return on assets | (38.41%) | (15.81%) | Fail | 0 |
| Cash flow above net income | 9.82m | 40.29m | Pass | 1 |
| Falling long-term leverage | 0.23 | 0.35 | Pass | 1 |
| Rising current ratio | 1.79 | 1.26 | Pass | 1 |
| No new shares issued | 89,032,500 | 75,516,000 | Fail | 0 |
| Rising gross margin | 91.48% | 97.03% | Fail | 0 |
| Rising asset turnover | 0.18 | 0.38 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| ANAB AnaptysBio, Inc. compare | 5 |
| NKTR Nektar Therapeutics compare | 3 |
| AAPG Ascentage Pharma Group International - Unsponsored ADR | 3 |
| INBX Inhibrx Biosciences, Inc. compare | 2 |
| OMER Omeros Corporation compare | 2 |
| GHRS GH Research PLC compare | — |
| TYRA Tyra Biosciences, Inc. compare | — |
| ORIC Oric Pharmaceuticals, Inc. compare | — |
| RAPP Rapport Therapeutics, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover